Q3 Earnings Season Winners: 3 Companies Raising Guidance

BWX Technologies (BWXT), Johnson & Johnson (JNJ), and UnitedHealth Group (UNH) raised FY26 guidance after strong Q3 earnings. BWXT reported 18% revenue growth and raised EPS guidance to $4.70–$4.80. JNJ saw 5.9% sales growth and increased EPS outlook to $11.10. UNH improved medical cost trends and raised EPS guidance to at least $20.50. All three companies cited improving business trends.

Original reporting
Published Nov 10, 2026, 12:12 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 4:42 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Q3 Earnings Season Winners: 3 Companies Raising Guidance — source image
Decision brief

The 30-second read

$BWXTBullishLow
01

Why it matters

While the guidance updates are positive, they repeat information already public, limiting new trading opportunities.

02

Market read

Guidance lifts may provide modest upside for each stock but are largely already priced in.

03

What to watch

Potential regulatory or supply‑chain risks in nuclear and healthcare segments could temper upside.

Relevance 4/10Novelty 2/10Timing: same day

Background

The article recaps recent FY26 guidance raises for three large U.S. companies after their quarterly results, which were released weeks earlier.

Company-level read

Ticker impact

$BWXTBullishHigh confidence
Context

BWX Technologies raised FY26 adjusted EPS guidance to $4.70‑$4.80 after reporting 18% revenue growth and a 72% jump in commercial sales.

Expected impact

likely upward pressure as investors price in higher EPS expectations

Evidence & confidence

Management's guidance lift follows solid quarterly results, indicating continued momentum in the nuclear segment.

$JNJBullishHigh confidence
Context

Johnson & Johnson increased FY26 adjusted EPS midpoint to $11.10 after a 5.9% revenue rise to $25.4 bn, driven by Innovative Medicine growth.

Expected impact

moderate upside as the market absorbs the higher EPS target

Evidence & confidence

The EPS lift, though small, reflects steady sales growth and may lift sentiment toward the stock.

$UNHBullishHigh confidence
Context

UnitedHealth Group raised FY26 adjusted EPS outlook to at least $20.50 after medical care ratio improved to 88.4% and operating earnings rose to $6.6 bn.

Expected impact

potential upward pressure as investors value improved cost ratio and earnings expansion

Evidence & confidence

Improved medical care ratio and higher operating earnings underpin the EPS upgrade, supporting a bullish view.

Market effects

Highlights strength in healthcare and nuclear components sectors, possibly boosting related peers.

U.S. large‑cap health and industrial stocks may see modest gains.

Limited; primarily U.S. equity impact.

Counterpoint

Guidance lifts are modest relative to company size; price may already reflect expectations.

Key entities

  • BWX Technologies

    Nuclear components and services provider.

  • Johnson & Johnson

    Diversified health and consumer products firm.

  • UnitedHealth Group

    Health insurance and services conglomerate.

Related articles

$UNHMed

UnitedHealth and other insurance stocks drag down the Dow after CMS proposes new anti-fraud rule

UnitedHealth (UNH), Humana (HUM), Cigna (CI), and CVS Health (CVS) stocks fell 8%, 8%, 2%, and 3% respectively, dragging down the Dow after CMS proposed a new anti-fraud rule. The rule, called CRUSH, aims to increase audits and recover improper payments, potentially saving $90B over 10 years. Oppenheimer analysts expect legal challenges and note savings may not be broad.

$JNJMed

RSV Vaccine Cuts Lower Respiratory Disease in Older Adults

A phase 3 trial showed Johnson & Johnson's RSV vaccine was 73% effective in preventing lower respiratory tract disease and 68% effective against acute respiratory infection in adults 60+. The vaccine had more local adverse reactions but similar serious adverse event rates compared to placebo. The study was terminated early for strategic reasons, with efficacy maintained across age groups. Johnson & Johnson funded the study, and several authors have ties to the company.

$CRMMed

Stock Market Today, Nov. 17: Stocks Slide on AI Chip and Tech Pressures, Salesforce Plummets 9%

U.S. stock indices fell, with the S&P 500 down 1.03%, Nasdaq 0.74%, and Dow 1.64%. Salesforce dropped 9.45% on security concerns and AI fears. UnitedHealth fell 5.42% due to Medicare & Medicaid proposals. Crypto stocks declined with Bitcoin down 20% in a month. Nvidia's earnings beat expectations, boosting after-hours trading. Gold and 10-Year Treasury yield also declined.